Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study
| Autor: | Marc K. Drezner, Peter L. Lakatos, J-Y Reginster, Dieter Felsenberg, Paul D. Miller, Claus Christiansen, Cyrus Cooper, Jan J. Stepan, Maria Greenwald, B. Bonvoisin, Pierre D. Delmas, N. Mairon, Lucy Rowell, Ronald Emkey, Silvano Adami, Stuart L. Silverman |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
ibandronate
bisphosphonate medicine.medical_specialty Bone density medicine.medical_treatment Immunology Osteoporosis Administration Oral Placebo Ibandronic acid Drug Administration Schedule General Biochemistry Genetics and Molecular Biology law.invention monthly osteoporosis non‐inferiority Double-Blind Method Rheumatology Randomized controlled trial Bone Density law Internal medicine medicine Humans Immunology and Allergy Femur Dosing Ibandronic Acid Osteoporosis Postmenopausal Aged Aged 80 and over Lumbar Vertebrae Bone Density Conservation Agents Diphosphonates Dose-Response Relationship Drug business.industry Middle Aged Bisphosphonate medicine.disease Surgery Extended Report Treatment Outcome Tolerability Female Hip Joint business medicine.drug |
| Zdroj: | Annals of the Rheumatic Diseases. 65:654-661 |
| ISSN: | 0003-4967 |
| Popis: | BACKGROUND: Reducing bisphosphonate dosing frequency may improve suboptimal adherence to treatment and therefore therapeutic outcomes in postmenopausal osteoporosis. Once-monthly oral ibandronate has been developed to overcome this problem. OBJECTIVE: To confirm the 1 year results and provide more extensive safety and tolerability information for once-monthly dosing by a 2 year analysis. METHODS: MOBILE, a randomised, phase III, non-inferiority study, compared the efficacy and safety of once-monthly ibandronate with daily ibandronate, which has previously been shown to reduce vertebral fracture risk in comparison with placebo. RESULTS: 1609 postmenopausal women were randomised. Substantial increases in lumbar spine bone mineral density (BMD) were seen in all treatment arms: 5.0%, 5.3%, 5.6%, and 6.6% in the daily and once-monthly groups (50 + 50 mg, 100 mg, and 150 mg), respectively. It was confirmed that all once-monthly regimens were at least as effective as daily treatment, and in addition, 150 mg was found to be better (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|